Tildipirosin Injectable

Verify with FDA CVM →

327 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
327
Total Reports
208
Deaths Reported
6360.0%
Death Rate

Active Ingredients

Tildipirosin Injectable

Administration Routes

SubcutaneousUnknownIntramuscularParenteralOtherOralTopical

Species Affected

Cattle 252
Human 36
Unknown 35
Fish 2
Cat 1
Goat 1

Most Affected Breeds

Cattle (other) 105
Unknown 74
Crossbred Bovine/Cattle 40
Aberdeen Angus 27
Holstein-Friesian also known as Holstein 23
Jersey 15
Mixed (Cattle) 11
Cattle (unspecified) 7
Red Angus 6
Charolais 5

Most Reported Reactions

Death 184
Lack of efficacy - NOS 127
Lack of efficacy (bacteria) - NOS 32
INEFFECTIVE, ANTIBIOTIC 31
Death by euthanasia 16
Respiratory signs 13
Injection site swelling 12
Injection site pain 12
DEATH-TREATMENT FAILURE 11
Necropsy performed 11
CULTURE/TITER DATA ABNORMAL 9
Injection site bleeding 7

Outcome Breakdown

Died
197 (38.3%)
Ongoing
124 (24.1%)
Recovered/Normal
97 (18.8%)
Outcome Unknown
77 (15.0%)
Euthanized
18 (3.5%)
Recovered with Sequela
2 (0.4%)

Data Summary

Metric Value
Total adverse event reports 327
Reports involving death 208
Case-fatality rate (reported events) 6360.0%
Distinct species in reports 6
Distinct breeds in reports 19
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tildipirosin Injectable Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 327 adverse event reports referencing Tildipirosin Injectable, including 208 reports in which the animal died — a 6360.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tildipirosin Injectable. Reported administration routes include Subcutaneous, Unknown, Intramuscular, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tildipirosin Injectable reports are Cattle (252 reports), Human (36 reports), Unknown (35 reports), with Cattle accounting for the largest share. Within those species, Cattle (other) (105), Unknown (74), Crossbred Bovine/Cattle (40) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tildipirosin Injectable are Death (184), Lack of efficacy - NOS (127), Lack of efficacy (bacteria) - NOS (32), INEFFECTIVE, ANTIBIOTIC (31). Of the 515 reports with a coded outcome, Died is the leading category at 38.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tildipirosin Injectable.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial